Universität des Saarlandes
uni-saarland.deLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
66
Active
14
Phase 3
6
Total enrollment
163,969
Pipeline matrix
Showing 11 of 11 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pembrolizumab | — | — | — | — | 2 | ||
| Cisplatin | — | — | — | — | — | 1 | |
| cisplatin + 5-fluorouracil | — | — | — | — | — | 1 | |
| Alternative medications: carboplatin + 5-fluorouracil | — | — | — | — | — | 1 | |
| Alternative medications: carboplatin | — | — | — | — | — | 1 | |
| R-miniCHOP + Acalabrutinib | — | — | — | — | — | 1 | |
| R-miniCHOP | — | — | — | — | — | 1 | |
| durvalumab | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | — | 1 | |
| Recompensation | — | — | — | — | — | 1 |
Next readouts
- 2025-12-31
- 2026-01
- 2027-03
- 2029-02
- 2032-12
Top conditions
- Parkinson Disease2
- Chronic Heart Failure2
- Health Status2
- Obesity2
- Acute Decompensated Heart Failure2
- Cognitive Impairment2
- Parkinson´s Disease2
- Stress2
Frequently asked questions about Universität des Saarlandes
- How many clinical trials does Universität des Saarlandes have on ClinicalTrials.gov?
- Universität des Saarlandes is listed as the lead sponsor on 66 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universität des Saarlandes's trials are in Phase 3?
- 6 of Universität des Saarlandes's trials are in Phase 3, spread across 11 active drug programs.
- What therapeutic areas does Universität des Saarlandes focus on?
- Universität des Saarlandes's most-studied conditions on ClinicalTrials.gov are Parkinson Disease, Chronic Heart Failure, Health Status, Obesity, Acute Decompensated Heart Failure.
- When are Universität des Saarlandes's next clinical trial readouts?
- Universität des Saarlandes has 5 upcoming primary-completion readouts tracked here; the soonest is “Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure”, expected around 2025-12-31.